News

Barchart on MSN13m
Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?
With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
Moderna lays off 500 in latest cost-cutting move
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Moderna plans to slash 10% of workforce as COVID shot sales slow
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
Moderna cuts sales forecast on UK revenue delay, shares fall
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Moderna to lay off 10% of workforce
Moderna CEO Stephane Bancel said in a memo to employees that the company expects to reduce its workforce to fewer than 5,000 ...
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...
Moderna Logs Sales Beat Despite Declining Vaccine Demand
Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...
Moderna: RSV Upside Slim, Cash Burn Heavy
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...